Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

The Food Safety and Standards Authority of India (FSSAI) has stepped up enforcement across the food, beverage and FMCG sectors, with the drive gathering pace since July.

In recent weeks, FSSAI has acted against or scrutinised products and companies over misleading claims, hygiene and food-safety violations, non-compliant ingredients, labelling issues and failure to meet prescribed standards.

The action has covered packaged foods, liquor, edible oils, sweeteners and high-caffeine beverages.

What Has FSSAI Cracked Down On?

1. Dabur — “100%” Claims

FSSAI directed Dabur India to prohibit the sale of food products such as honey, cow ghee and edible oils carrying “100%” claims.

Dabur challenged the action, accusing FSSAI of favouring certain manufacturers. The company approached the Delhi High Court, which stayed the order, with Dabur arguing that the action was taken without allowing it to be heard.

Dabur also submitted that the “100%” claim is used by several other manufacturers. The matter will next be heard by the Delhi High Court on August 24.

2. Liquor Brands — Artificial Flavouring

The food safety regulator has banned the sale of select whisky and rum products from major liquor companies, including Diageo India’s United Spirits, after finding artificial or “nature-identical” flavouring that allegedly violates Indian food standards.

The affected products include United Spirits’ Antiquity Blue Whisky and Royal Challenge Whisky manufactured in Madhya Pradesh, Inbrew’s Bagpiper Deluxe Whisky and Old Cask Deluxe XXX Rum, and three variants of Old Monk produced by Mohan Rocky Springwater in Maharashtra.

3. VKC Nuts — licence suspended

The licence was suspended following serious food-safety and hygiene violations, including live insects in pistachios stored in the finished goods storage area, and heavy black mould and fungal growth observed on the walls and ceilings of the raw material storage area.

4. Chheda Specialities Foods — licence suspended

The Mumbai-based ethnic snack and namkeen manufacturer faced licence suspension over serious hygiene violations. Inspections reportedly found unhygienic handling, roof leakages, fungal growth near edible oil storage tanks and poor waste management.

5. Fortune Fryola — Vitamin D standards

Action was taken against AWL Agri Business after its fortified sunflower oil failed prescribed Vitamin D standards.

6. PIE Foods — monk fruit sweetener

Action involved related compliance issues. FSSAI also flagged product labels that lacked mandatory declarations and carried claims including “100% Monk Fruit Extract” and “Natural Ingredients”. Its e-commerce website also carried the claim “Doctor Recommended”.

7. High-caffeine beverages — “energy drink” claims

FSSAI has continued action over products using the term “energy drink” without meeting relevant standards. Brands involved include Red Bull, Monster, Sting and Adrenaline Rush.

Other Recent Actions

Switz Foods: Licence suspended over food-safety and hygiene violations.

Matri Drinking Water: Licence suspended over food-safety, storage and hygiene issues.

Noble Healthcare – Venolex Forte: Action over non-permitted ingredients and excessive Vitamin C.

Vatave Healthcare – Folineuro Syrup: Action over brain-function claims.

Global Healthfit Retail – Neuherbs True Vitamin: Action over product naming and claim-related compliance.

Why Does the Crackdown Matter?

Stronger enforcement could improve food quality, curb misleading claims and encourage manufacturers to comply with safety standards, experts say.

“Although late, this initiative of enforcement of correct ingredients of the products is very beneficial in the long-term health of the nation, especially the youth health, those who consume more of the packed items including beverages, canned food and drinks, fruit drinks and packed milk,” said Dr Mohsin Wali, Senior Consultant, Department of Medicine, Sir Ganga Ram Hospital, told HealthandMe.

Why Clear Labelling Matters

Dr Wali said food labels should be properly sized, readable and clearly displayed, with key information prominently placed rather than hidden on the sides or bottom of packaging.

He also said ingredients should be clearly identified rather than represented through codes. If an emulsifier is used, for example, the specific emulsifier should be named.

According to Dr Wali, stronger enforcement could help prevent diseases including obesity, PCOD, atherosclerosis, heart disease, stroke and hypertension.

Bruce Willis’ wife, Emma Heming Willis, has opened up about “wrestling” with guilt over celebrating her 50th birthday while her husband continues to battle dementia.

The former model turned 50 in June and, in an Instagram post, wrote, “I’m ready for this new decade and all it has to offer.”

However, she admitted she was initially wary of celebrating because of her husband’s dementia struggles. At the behest of friends and family, she decided to mark the milestone. Still, she said she continued to wrestle with guilt about celebrating while Bruce Willis is living with a terminal condition.

‘I’m Always Carrying’ Guilt

Speaking on a podcast, Emma said she had not been “in the celebratory feelings” recently and was unsure whether she wanted to do anything for her 50th birthday.

A friend encouraged her to celebrate, reminding her that she did not want to miss marking the milestone.

“I always wrestle with it, you know?” she said. “I think guilt is something that I am always carrying, but I’ve learned that it is really not helpful. What I know is I always go back to what would my husband want for me?”

She explained that even ordinary moments of celebration can bring guilt, as she often feels there are other things she should be doing for her husband.

“There are moments [when] you want to do something, [but] you say, ‘Oh, but I can’t, I can’t. There’s a million other things that I need to be doing for him.’”

However, Emma said she believes the Die Hard star would want her to enjoy the milestone with the people she loves. She said he “would want me to have a big fun bash” and “would want me to celebrate my life with my friends and family.”

In March 2023, Bruce Willis, who dominated Hollywood during his career, was diagnosed with frontotemporal dementia (FTD), a degenerative condition that can affect communication, behavior and motor skills.

Emma On The Emotional Toll Of Caregiving

This is not the first time Emma has spoken about the guilt and emotional challenges of caring for her husband.

Emma, who has been his primary caregiver, previously said that Bruce is supported, loved and cared for by the family.

“You know, we’re doing well. My husband is supported and loved and we’re doing the best we can under the circumstances,” she said during an interview on Today in May.

Last year, at the Women’s Alzheimer’s Movement Forum in Las Vegas, Emma also spoke about the emotional impact of Bruce’s diagnosis and the unseen toll of caregiving. She recalled the day Bruce was formally diagnosed as one that left her feeling “lost, isolated and afraid.”

Caregiving is a respectable position, but it's also a challenging and thankless one. For those who are caring for loved ones with dementia or other chronic illnesses, the stress of "keeping it all together" can result in a condition called caregiver burnout.

"Caring for someone is the most intimate and demanding work of love," Emma explained, "but when you're not noticed or supported, it begins to undermine your health—mentally and physically."

Canada has never reported a case of Ebola, yet Nova Scotia has become one of the first places in the world where humans are receiving an experimental vaccine against the deadly virus.

The first participant received Moderna’s experimental mRNA-1469 vaccine in Truro, Nova Scotia, on August 3. The Phase 1 trial is being conducted at three Canadian sites in Truro, Halifax and Toronto and aims to enrol around 80 healthy adults.

Why Is Canada Testing An Ebola Vaccine?

Also read: Ebola Outbreak in Congo Surpasses 4,000 Cases; Officials To Probe Whether Bundibugyo Virus Is Mutating

The current outbreak in the Democratic Republic of Congo (DRC) is being caused by Bundibugyo ebolavirus, a relatively rare Ebola species for which there is currently no approved vaccine or treatment.

More than 3,800 infections and over 1,700 deaths have been reported in the outbreak, making it the second-largest Ebola outbreak on record.

Existing Ebola vaccines are largely designed to protect against the Zaire species, which caused previous major outbreaks. They cannot simply protect the masses against Bundibugyo.

This has created a dangerous situation: an outbreak is already underway, but scientists do not yet have a licensed vaccine specifically targeting the strain driving it.

Why Nova Scotia Is Chosen For Testing Ebola Vaccine?

Also read: Ebola Outbreak: Moderna Begins First Human Trial Of Bundibugyo Vaccine As Cases Rise to 3,748

Nova Scotia was not selected because Ebola is circulating there. In fact, Health Canada says there have been no cases of Ebola disease in Canada.

But, the province has something far more useful for an early vaccine trial: years of experience conducting vaccine research.

The Canadian Center for Vaccinology, a collaboration involving Dalhousie University, IWK Health and Nova Scotia Health, has extensive experience in vaccine development and clinical trials.

Moderna said Canada was selected because of its experience with early-stage clinical trials, Health Canada's regulations and the country's long history of contribution to research on filoviruses, the family of viruses that includes Ebola.

“Canadian researchers and participants are contributing an important first step in a broader international effort to develop a vaccine against a form of Ebola for which no approved protection is currently available,” Hamilton Bennett, Moderna's executive director of global health security and R&D partnerships, said.

About The Ebola Trial In Nova Scotia

Phase 1 trials primarily examine whether a vaccine is safe, what dose should be used and whether it produces an immune response.

Participants are given the vaccine, not the Ebola virus, and they cannot get Ebola from the vaccine trial itself.

The mRNA-1469 vaccine uses the same mRNA technology that Moderna used for its COVID-19 vaccine. It is designed to teach the immune system to recognise Bundibugyo virus and produce an immune response without exposing volunteers to the live virus.

The Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to US$50 million to support Moderna's vaccine development. If the vaccine eventually proves successful, Moderna has committed to making at least 500,000 doses available to low- and middle-income countries.

Dalhousie researchers are studying the Bundibugyo virus itself. Recent work helped identify a genetically distinct variant circulating in the DRC and investigate possible treatment options.

Phase 1 of the trial can establish safety and immune responses, but larger Phase 2 and Phase 3 studies will be needed to determine whether the vaccine actually prevents Ebola disease.